MaxCyte Inc (MXCT) Stock Rating Reaffirmed by Panmure Gordon

Panmure Gordon reissued their buy rating on shares of MaxCyte Inc (LON:MXCT) in a research note published on Tuesday morning. They currently have a GBX 170 ($2.22) target price on the stock.

Shares of MaxCyte (LON:MXCT) opened at 83.00 on Tuesday. The company’s market cap is GBX 36.11 million. The firm has a 50-day moving average of GBX 84.56 and a 200-day moving average of GBX 82.20. MaxCyte has a 12-month low of GBX 75.00 and a 12-month high of GBX 86.38.

MaxCyte Company Profile

MaxCyte, Inc focuses on cell-based medicines. The Company’s cell modification technology, Flow electroporation, is used for discovery, development and manufacture of small molecule, biologic and cell-based therapeutics. The Company’s products include instruments, processing assemblies and insourcing services.

Receive News & Ratings for MaxCyte Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte Inc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.